Ithaka Group LLC lowered its holdings in Insulet Co. (NASDAQ:PODD – Free Report) by 1.5% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 29,821 shares of the medical instruments supplier’s stock after selling 468 shares during the quarter. Insulet accounts for about 1.3% of Ithaka Group LLC’s holdings, making the stock its 26th biggest position. Ithaka Group LLC’s holdings in Insulet were worth $6,941,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors also recently bought and sold shares of PODD. Blue Trust Inc. lifted its holdings in Insulet by 84.1% in the third quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier’s stock valued at $30,000 after acquiring an additional 58 shares during the period. International Assets Investment Management LLC acquired a new position in shares of Insulet during the 2nd quarter worth $32,000. Venturi Wealth Management LLC raised its stake in shares of Insulet by 633.3% during the 3rd quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier’s stock worth $36,000 after buying an additional 133 shares during the last quarter. UMB Bank n.a. raised its stake in shares of Insulet by 81.0% during the 2nd quarter. UMB Bank n.a. now owns 181 shares of the medical instruments supplier’s stock worth $37,000 after buying an additional 81 shares during the last quarter. Finally, CVA Family Office LLC raised its stake in shares of Insulet by 138.1% during the 2nd quarter. CVA Family Office LLC now owns 250 shares of the medical instruments supplier’s stock worth $50,000 after buying an additional 145 shares during the last quarter.
Insulet Stock Down 1.3 %
PODD opened at $262.99 on Friday. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. The stock has a market capitalization of $18.45 billion, a price-to-earnings ratio of 45.03, a price-to-earnings-growth ratio of 4.01 and a beta of 1.22. The business has a 50-day moving average of $240.74 and a two-hundred day moving average of $209.99. Insulet Co. has a 12 month low of $160.19 and a 12 month high of $279.40.
Analyst Upgrades and Downgrades
Read Our Latest Research Report on Insulet
About Insulet
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.
See Also
- Five stocks we like better than Insulet
- The Risks of Owning Bonds
- MicroStrategy’s Stock Dip vs. Coinbase’s Potential Rally
- 3 Best Fintech Stocks for a Portfolio Boost
- Netflix Ventures Into Live Sports, Driving Stock Momentum
- Investing in Commodities: What Are They? How to Invest in Them
- Snowflake Melts Up as Analysts Shift Gears; Higher Prices To Come
Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Co. (NASDAQ:PODD – Free Report).
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.